Advancements in Cancer Immunotherapies

Overview

Journal Vaccines (Basel)

Date 2023 Jan 21

PMID 36679904

Authors

Ruchi Roy

Sunil Kumar Singh

Sweta Misra

Affiliations

Soon will be listed here.

Abstract

Recent work has suggested involvement of the immune system in biological therapies specifically targeting tumor microenvironment. Substantial advancement in the treatment of malignant tumors utilizing immune cells, most importantly T cells that play a key role in cell-mediated immunity, have led to success in clinical trials. Therefore, this article focuses on the therapeutic approaches and developmental strategies to treat cancer. This review emphasizes the immunomodulatory response, the involvement of key tumor-infiltrating cells, the mechanistic aspects, and prognostic biomarkers. We also cover recent advancements in therapeutic strategies.

Citing Articles

Metabolically activated and highly polyfunctional intratumoral VISTA regulatory B cells are associated with tumor recurrence in early-stage NSCLC.

Lo Tartaro D, Aramini B, Masciale V, Paschalidis N, Lofaro F, Neroni A Mol Cancer. 2025; 24(1):16.

PMID: 39810191 PMC: 11730485. DOI: 10.1186/s12943-024-02209-2.

Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.

Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal S J Clin Med. 2024; 13(21).

PMID: 39518676 PMC: 11546714. DOI: 10.3390/jcm13216537.

Parasites revive hope for cancer therapy.

Eissa M, Salem A, El Skhawy N Eur J Med Res. 2024; 29(1):489.

PMID: 39367471 PMC: 11453045. DOI: 10.1186/s40001-024-02057-2.

Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface.

Gayen S, Mukherjee S, Dasgupta S, Roy S Apoptosis. 2024; 29(11-12):1879-1913.

PMID: 39354213 DOI: 10.1007/s10495-024-02022-8.

Cytoprotective effect of garlic alone versus co-administration of garlic and resveratrol in adriamycin-induced lung toxicity in albino rat: light microscopic, ultrastructural and immunohistochemical study.

Rashed N, Ismail O J Mol Histol. 2024; 55(5):835-849.

PMID: 39105941 DOI: 10.1007/s10735-024-10235-z.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Zhang J, Lu W, Ye F, Chen H, Zhou C, Xie X . Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma. Int J Gynecol Cancer. 2007; 17(2):478-83. DOI: 10.1111/j.1525-1438.2007.00786.x. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Olivier T, Haslam A, Prasad V . Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Netw Open. 2021; 4(12):e2138793. PMC: 8672232. DOI: 10.1001/jamanetworkopen.2021.38793. View

Marrone K, Brahmer J . Using Immune Checkpoint Inhibitors in Lung Cancer. Oncology (Williston Park). 2016; 30(8):713-21. View

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Liu R, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A . Densely granulated murine NK cells eradicate large solid tumors. Cancer Res. 2012; 72(8):1964-74. PMC: 3680344. DOI: 10.1158/0008-5472.CAN-11-3208. View

10.

Zahavi D, Weiner L . Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020; 9(3). PMC: 7551545. DOI: 10.3390/antib9030034. View

11.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

12.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

13.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

14.

Lu X, Ding Z, Cao Y, Liu C, Habtetsion T, Yu M . Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol. 2015; 194(4):2011-21. PMC: 4324150. DOI: 10.4049/jimmunol.1401894. View

15.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

16.

Yamaguchi H, Hsu J, Yang W, Hung M . Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022; 19(5):287-305. DOI: 10.1038/s41571-022-00601-9. View

17.

Christiansen A, Detmar M . Lymphangiogenesis and cancer. Genes Cancer. 2012; 2(12):1146-58. PMC: 3411123. DOI: 10.1177/1947601911423028. View

18.

Hatae R, Chamoto K . Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy. Rinsho Ketsueki. 2016; 57(10):2224-2231. DOI: 10.11406/rinketsu.57.2224. View

19.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

20.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View